Pharmaceutical Companies

Amyl Therapeutics will expand its laboratory facilities at the LegiaPark life sciences campus in Liège, Belgium, to accommodate its growing research programme.

The acquisition will give Lilly access to Merida’s technology for developing biologics that selectively eliminate disease-causing autoantibodies.

The decision follows positive results from the Phase III VALOR trial (NCT05437263), which showed that Lisraya improved several measures of dermatomyositis disease activity.

Biohaven is currently evaluating the therapy in the Phase II/III RISE3 study, with results expected in the second half of 2026.

Minapharm’s candidate is the fifth Bundibugyo-specific vaccine supported by CEPI as the Democratic Republic of the Congo (DRC) responds to a rapidly escalating outbreak.

The issuance forms part of Emzor’s broader US$29.6 million bond programme, which is designed to provide capital for the company’s growth and operational needs.

Hanmi is developing the HM17321 therapy as a potential first-in-class treatment that could promote weight loss while helping preserve lean body mass.

Seralutinib is an investigational treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The company’s focus on both non-potent and high-potency APIs reflects the range of projects handled at the site, from conventional small-molecule development to programs requiring additional containment and specialized handling.

As part of the agreement, Charles River will use technologies such as next-generation sequencing (NGS) to support chemistry, manufacturing and controls (CMC) activities associated with the vaccine programme.